Aloe Blacc’s fame means nothing in biotech (and that’s the point)
(techcrunch.com)
61.
62.
The Download: how humans make decisions, and Moderna’s “vaccine” word games
(technologyreview.com)
63.
Big Pharma Is Turning to China for the Newest Drug Ideas
(feeds.content.dowjones.io)
64.
Gilead to Buy German Biotech Tubulis for $3 Billion for Experimental Cancer Drugs
(feeds.content.dowjones.io)
65.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
(feeds.content.dowjones.io)
66.
Peptides: where to begin?
(news.ycombinator.com)
67.
Neurocrine to Buy Soleno for $2.9 Billion
(feeds.content.dowjones.io)
68.
Why the US needs a unified, mission-based strategy for health innovation
(feeds.nature.com)
69.
70.
71.
72.
73.
Novartis to Buy Biotech Excellergy for Up to $2 Billion
(feeds.content.dowjones.io)
74.
75.
The most innovative biotech companies of 2026
(feeds.feedburner.com)
76.
Lab-grown oesophagus restores pigs’ ability to swallow
(feeds.nature.com)
77.
The real story behind China’s technology triumph
(feeds.nature.com)
78.
Opinion | India’s Boundless Biotech Potential
(feeds.content.dowjones.io)
79.
BioNTech Shares Fall After Co-Founders Plan Exit and Outlook Misses Forecasts
(feeds.content.dowjones.io)
80.
Biotech investor set to lead US National Science Foundation
(feeds.nature.com)
81.
China’s biotech boom: why the nation must collaborate to stay ahead
(feeds.nature.com)
82.
Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion
(feeds.content.dowjones.io)
83.
Show HN: BioTradingArena – Benchmark for LLMs to predict biotech stock movements
(news.ycombinator.com)
84.
Merck No Longer in Talks to Buy Revolution Medicines
(feeds.content.dowjones.io)
85.
Opinion | America Is Losing the Biotech Fight to China
(feeds.content.dowjones.io)
86.
The Download: cut through AI coding hype, and biotech trends to watch
(technologyreview.com)
87.
Three technologies that will shape biotech in 2026
(technologyreview.com)
88.
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons.
(feeds.content.dowjones.io)
89.
Funding for Risky Biotechs Is Returning
(feeds.content.dowjones.io)
90.
Opinion | Why Is Boston’s Biotech Industry Struggling?
(feeds.content.dowjones.io)